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Objectives: The aim of this study was to review reimbursement environment as well
as pricing and reimbursement requirements for drugs in selected Central and Eastern
Europe (CEE) countries.
Methods: A questionnaire-based survey was performed in the period from November
2016 to March 2017 among experts involved in reimbursement matters from CEE
countries: Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland,
Slovakia, and Romania. A review of requirements for reimbursement and implications
of Health Technology Assessment (HTA) was performed to compare the issues in
above-mentioned countries. For each specified country, data for reimbursement costs,
total pharmaceutical budget, and total public health care budget in the years 2014 and
2015 were also collected. Questionnaires were distributed via emails and feedback data
were obtained in the same way. Additional questions, if any, were also submitted to
respondents by email. Pricing and reimbursement data were valid for March 2017.
Results: The survey revealed that the relation of drug reimbursement costs to total
public healthcare spending ranged from 0.12 to 0.21 in the year 2014 and 2015 (median
value). It also revealed that pricing criteria for drugs, employed in the CEE countries, were
quite similar. External reference pricing as well as internal reference pricing were common
in mentioned countries. Positive reimbursement lists were valid in all countries of the CEE
region, negative ones were rarely used; reimbursement decisions were regularly revised
and updated in the majority of countries. Copayment was common and available levels of
reimbursement differed within and between the countries and ranged from 20 to 100%.
Risk-sharing schemes were often in use, especially in the case of innovative, expensive
drugs. Generic substitution was also possible in all analyzed CEE countries, while some
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made it mandatory. HTA was carried out in almost all of the considered CEE countries
and HTA dossier was obligatory for submitting a pricing and reimbursement application.
Conclusions: Pricing and reimbursement requirements are quite similar in the CEE
region although some differences were identified. HTA evaluations are commonly used
in considered countries.
Keywords: pricing, reimbursement, CEE, pharmaceutical regulation, drug policy
INTRODUCTION
In the European Union (EU) pricing and reimbursement of
pharmaceuticals is primarily a national competence; that is
reason for different pharmaceutical regulation systems currently
applied in these countries. A review of pharmaceutical pricing
and reimbursement systems in the countries of Western Europe
was performed in some publications (Vogler et al., 2011; Panteli
et al., 2016; Allen et al., 2017). However, an urgent need for review
of data on the pharmaceutical systems in the Central and Eastern
Europe (CEE) countries as well as a strong interest in pricing and
reimbursement strategies applied in these countries is observed.
In the EU, medicines can be placed on the market only if
they have received a marketing authorization from the European
Commission or from competent national authorities as EU
legislation provides harmonized rules of drug authorization1.
Pharmaceutical therapies are often subsidized by national
reimbursement systems in order to provide the adequate access
of medicines to citizens, which influences the prescription and
utilization of medicines. Member States are free to adopt their
own pricing and reimbursement regulations, as long as these are
in line with the minimal procedural requirements of Directive
89/105/EEC2,3 issued by the European Commission to ensure the
transparency of national pricing and reimbursement regulations
(for this reason, it is commonly referred to as the Transparency
Directive).
The Transparency Directive requires that decisions related
to the reimbursement of drugs have to be taken within 90
days of application (and 180 days for reimbursement and
pricing decisions); the directive also providesmajor requirements
with respect to individual pricing and reimbursement decisions
which:
• Must be announced to the applicant and have to state of
reasons based on verifiable and objective criteria;
• Must be open to appeal in court at national level3.
As more specific and detailed requirements in pricing and
reimbursement policy are set on national level, we performed a
review of currently established drug policies in CEE countries to
compare and provide data to fill a significant knowledge gap.
1http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/
general_content_001595.jsp&mid=WC0b01ac0580b18a3d (Accessed on June 02,
2017)
2https://ec.europa.eu/growth/sectors/healthcare/competitiveness/products-
pricing-reimbursement/transparency-directive_en (Accessed on June 02, 2017)
3Council Directive 89/105/EEC of 21 December 1988 relating to the transparency
of measures regulating the prices of medicinal products for human use and their
inclusion in the scope of national health insurance systems. http://eur-lex.europa.
eu/legal-content/EN/TXT/?uri=CELEX:31989L0105 (Accessed on June 02, 2017)
Positive or negative reimbursement lists are in use to
provide information on reimbursement or contraindication to
reimbursement of specific drugs (Panteli et al., 2016). Medicines
present in the Positive Drug List (PDL) are reimbursed at
different levels due to partial or full reimbursement. For drugs
which are reimbursed at a level lower than 100%, patients’
copayment is needed; medicines included in negative lists are not
reimbursed in a specific country; reimbursement categories are
country specific (Vogler, 2012). For drugs which are expensive
and used chronically the reimbursement levels are usually higher
than for drugs used temporarily (e.g., antibiotics).
To have a drug reimbursed, marketing authorization holder
(MAH) has to submit an application with a number of
attachments, including health technology assessment (HTA)
dossier (Panteli et al., 2016). HTA is useful for reimbursement
decisions for new molecules to assess value for money; it usually
includes economic evaluation of cost effectiveness and budget
impact analysis (BIA), clinical effectiveness, and safety profile
assessment of a particular drug in relation to the therapeutic
alternative (Panteli et al., 2016; Zawada and Mäkelä, 2017).
Medicines which are not reimbursed can be financed from
public funds within compassionate use programs. This way of
public coverage for pharmacotherapy allows for reimbursement
of specific medicines for particular patient after approval of
individual application (Balasubramanian et al., 2016).
Many European countries applied a reference price system,
with a maximum reimbursement level specified for groups of
interchangeable pharmaceuticals (Panteli et al., 2016). External
reference pricing (also known as international reference pricing
or external price referencing) was frequently employed strategy
in price regulation comparing the prices of the same product
in other countries. External reference pricing is usually applied
for reimbursable, original drugs, but vary substantially across
countries. Another reference system is internal reference pricing,
that is, comparing the price of a product to the prices of
similar products in the same country, or in the same therapeutic
class, or in the same International Nonproprietary Name (INN)
in order to set the reference price as a function of prices of
domestic substitutes. Physicians are allowed or even obliged to
prescribe INN instead of the trade name. It allows the generic
substitution—patient is offered to buy the cheapest or any other
product with a particular active substance (Panteli et al., 2016).
For some medicines, the risk-sharing schemes or risk-sharing
agreements (RSAs) could be applied (Panteli et al., 2016); based
on such agreements MAH is obliged to take the proportion
of risk and expenditure resulting from financing of the new
pharmacotherapy from public resources.
The country sample was chosen to include all CEE countries
which are the “new” EU members, that is, which joined the
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EU this century: Bulgaria, Croatia, Czech Republic, Estonia,
Hungary, Latvia, Lithuania, Poland, Slovakia, and Romania.
Croatia is the newest member of the EU, as it joined in 2013,
Bulgaria and Romania entered EU in 2007, and the remaining
of the included countries joined the EU in 20044.
The main goal of this study was to illustrate in a systematic,
comparative manner current requirements and regulations
influencing pharmaceutical systems in considered European
countries. The investigation included: pricing and price updates
criteria, patient copayments, generic substitution, health
technology assessment implementation and comprehensive
review of reimbursement requirements.
MATERIALS AND METHODS
We performed country-based reviews that provided a detailed
description of pharmaceutical system and policy initiatives which
are valid or under development in a specific country; it was
carried out in the period from November 2016 to March 2017.
Each review was produced by 1 or more leading national experts
in pricing and reimbursement policy; the study was supervised
by the project coordinator.
Experts from the participating countries provided in-
depth data valid for sophisticated assessment of pricing and
reimbursement as well as data on expenditures on specified
pharmacotherapies. In order to facilitate comparisons between
countries, reviews were based on a questionnaire survey,
covering all the project objectives; the questionnaire was
prepared after consideration of some previously performed
studies (Panteli et al., 2016; Kawalec et al., 2017). The first
part of our survey included questions referring to general
pricing and reimbursement environment in reference countries.
Additionally, data on total public healthcare expenditure, total
reimbursement costs, market share of generics in the years
2014 and 2015 were provided. In the subsequent parts of our
study, more accurate data on pricing and reimbursement policy
were provided. Additionally, it included specific reimbursement
implications embracing generic substitution, reimbursement
control, and reimbursement decision-making process, including
HTA dossier requirements.
Questionnaires were distributed via emails and feedback data
were obtained in the same way. An interactive review with
the contributors was performed to obtain the optimal range of
information needed and to get additional answers in case of
any lacking data. Pricing and reimbursement data were valid for
March 2017.
RESULTS
General Overview
We reviewed data on total public expenditure (in Euro) on
reimbursement of medicines and total public health care budget
(in Euro) in the years 2014 and 2015 for considered countries. For
4https://ec.europa.eu/neighbourhood-enlargement/policy/from-6-to-28-
members_en (Accessed on June 02, 2017)
several countries—Bulgaria, Croatia, Lithuania, and Romania—
data concerned total public healthcare expenditures were not
available. It was revealed that the relation of drug reimbursement
costs to total public healthcare spending in the year 2014 ranged
from 0.12 to 0.21 and the median value was 0.18. For the
year 2015 more limited data were available (no data concerned
reimbursement costs for Hungary), but the ratio was quite similar
and equaled 0.12 to 0.21 and median value was 0.15 (see Table 1
for details). Observed differences in pharmaceutical expenditures
should be interpreted in conjunction with the different price
levels and volume composition of consumption as well as impact
on measurement by dispensation practices.
We also measured timelines for pricing and reimbursement
decisions among the analyzed countries; in majority of them a
180 days deadline for decision-making process, with accordance
to the EU Transparency Directive, was applied.
In Hungary, the official timelines depend on the type of a
procedure applied: for a standard procedure it is usually 90 days
but for a simplified procedure 60 days is enough to issue a
reimbursement decision5. In Romania, the decision is announced
to the applicant within 90 days from the submission of the
complete documentation. If the evaluation of requested drug has
not been approved in price submission, the time for final decision
is extended by next 90 days. In Czech Republic, the decision is
made within 75 days in the case of application only for price
or only for reimbursement (165 for joint application for price
and reimbursement). Since 2012, a special type of short 30-days
procedure is available for generic and biosimilar products. In
Estonia, the reimbursement decision for the standard (simplified)
procedure is made within 90 days from submission, and when
the new HTA dossier is submitted, the decision is made within
180 days6. In Lithuania preliminary recommendation alongside
with assessment report on therapeutic value, pharmacoeconomic
value and budget impact is published on the website of the
Ministry of Health and informs the Applicant within 80 days
from submission of the dossier7.
Review of Pricing Criteria
In all considered countries an external (international) reference
pricing as well as internal reference pricing is common. The
number of reference countries differs significantly in case of
external price referencing: the lowest number is used in Estonia
(3 reference countries6) as well as Croatia (5), and the highest
numbers were reported for Hungary (31) and Poland (31).
We also analyzed influence of considered countries on
others in terms of reference pricing; Cyprus, Iceland, Malta,
Luxembourg, and Norway occurred as reference countries quite
5Act XCVIII of 2006 on the Safe and Economic Supply and Distribution of
Medicines and TherapeuticMedical Devices. 2006; [cited 4 April 2017]. https://net.
jogtar.hu/jr/gen/hjegy_doc.cgi?docid=A0600098.TV (Accessed on June 02, 2017)
6Regulation ofMinistry of Social Affairs: Procedure for drafting and amendment of
a list of medicinal products of the Estonian Health Insurance Fund and the content
of criteria for establishing the list and evaluators of compliance with the criteria.
https://www.riigiteataja.ee/en/eli/ee/SOM/reg/516062015002/consolide (Accessed
on June 02, 2017)
7Order of Minister of Health of Lithuania Nr., 159 (5 April 2002) https://www.e-
tar.lt/portal/lt/legalAct/TAR.E83CFAB10E7B (Accessed on June 02, 2017)
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TABLE 1 | Total public expenditure on reimbursement and total public healthcare budget (in thousands Euro; presented for 2014 and 2015).
Aspect required Bulgaria Croatia Czechia Estonia Hungarya–d Latvia Lithuaniag Polandi Romania Slovakiae,f
Total public expenditure (in Euro) on
reimbursement of drugs in 2014
544,014 667,500 2,089,560 109,753 1,028,000 118,930 190,600 2,453,500j 1,838,000 884,000
Total public health care budget (in
Euro) in 2014h
n/a n/a 10,261,656 924,727 5,020,590 776,287 n/a 18,382,789 n/a 4,217,012
Public reimbursement and total
public health care budget relation in
2014
n/a n/a 0.20 0.12 0.20 0.15 n/a 0.13 n/a 0.21
Total public expenditure (in Euro) on
reimbursement of drugs in 2015
559,353 702,300 2,293,856 112,801 n/a 124,300 197,500 2,558,466 1,774,000 905,000
Total public health care budget (in
Euro) in 2015h
n/a n/a 10,751,286 973,900 5,159,609 822,601 n/a 18,853,265 n/a 4,398,045
Public reimbursement and total
public health care budget relation in
2015
n/a n/a 0.21 0.12 n/a 0.15 n/a 0.14 n/a 0.21
n/a, Not available.
aPublic pharmaceutical spending in 2014 by the National Health Insurance Fund of Hungary: http://www.neak.gov.hu/felso_menu/szakmai_oldalak/publikus_forgalmi_adatok/
gyogyszer_forgalmi_adatok/gyogyszer_forgalmi_adatok_2014.html.
bCalculated on current exchange rate in 2014 by the Central Bank of Hungary.
cPublic pharmaceutical spending in 2015 by the National Health Insurance Fund of Hungary: http://www.neak.gov.hu/felso_menu/szakmai_oldalak/publikus_forgalmi_adatok/
gyogyszer_forgalmi_adatok/gyogyszer_forgalmi_adatok_2015.html.
dCalculated on current exchange rate in 2015 by the Central Bank of Hungary.
eSlovak Ministry of Finance, http://www.finance.gov.sk/Default.aspx?CatID=11158.
fNational Health Information Centre (NHIC), Slovak Republic, http://www.nczisk.sk/en/Pages/default.aspx.
g Includes only reimbursed medicines for outpatient care; does not include expenses for centrally purchased reimbursed medicines and expenses for medicinal aids.
hOrganization for Economic Co-operation and Development, Health expenditure and financing, Current expenditure on health, Government schemes and compulsory contributory health
care financing schemes, stats.oecd.org.
iNational Health Fund, spending on reimbursement, www.nfz.gov.pl.
jCosts of reimbursement of drugs by the NHF (ambulatory list, catalog of chemotherapy, drug programs); costs of drugs administered in hospitals as a part of DGR procedures were
not included.
rarely, while Slovakia, Czech Republic, and Lithuania were used
as a reference most often in the analyzed CEE countries (see
Tables 2, 3 for detail).
In the case of Bulgaria, for products containing the same
INN which were in the same pharmaceutical form the value
of reimbursement is set at the level of the cheapest product
determined by the cost per defined daily dose8. The ex-factory
price of the generic version of a medicine listed in the PDL
may not exceed 70% of the ex-factory price of the reference
product in the PDL. The generic pricing is also subject to
external referencing, so the established ex-factory price cannot
be higher than the lowest manufacturer price in the reference
countries.
In Croatia, the basis for determining the comparative
wholesale price of the drug is the wholesale price of the same drug
(a drug with the same generic name and the same pharmaceutical
form) in Italy, Slovenia, and the Czech Republic, and, if necessary,
in Spain and France. The Croatian Health Insurance Fund
(CHIF) established standards and price settings for services
covered by the Fund and it is responsible for pricing and the
reimbursement decisions on drugs andmedical devices which are
8Ministry of Health of the Republic of Bulgaria and the International Bank for
Reconstruction and Development, Final Report on Health Financing Diagnostic
and Review of Envisaged Reforms, May 2015.
included in the CHIF list of drugs by the experts’ council of the
CHIF—Committee for Medicines9,10.
For Czech Republic, reference countries are all countries of
the EU except Austria, Bulgaria, Cyprus, Estonia, Germany,
Luxembourg, Malta, and Romania. External price referencing
embraces at least 3 prices. Exclusion of the price extremes
compared to other reference countries is applied11. The lowest
price is considered a price extreme if it is lower by more than
20% of the average of 2nd and 3rd lowest price found in other
reference countries. If there is no price extreme identified, ex-
factory price should be equaled to an average of 3 lowest prices.
In the case of a price extreme, the lowest price is excluded and
ex-factory price is set on the level of an average of 2nd and 3rd
lowest prices, or based on a price agreement concluded between
the public payer and MAH if it would lead to a lower price18.
If a pharmaceutical (with the exception of highly innovative
drugs) is not on the market in at least 3 reference basket states,
price agreement can be used. If none of the above-mentioned
procedures is applicable, the price is set as the maximum
ex-factory price of the closest therapeutically comparable
9Medicinal Products Act (“Official Gazette”, no. 76/2013) http://www.zakon.hr/z/
399/Zakon-o-lijekovima (Accessed on June 02, 2017).
10The Ordinance on the criteria for marketing authorization of drugs on the
Basic and Additional drug list of CHIF, http://www.hzzo.hr/zdravstveni-sustav-
rh/pravilnik-o-mjerilima-za-stavljanje-lijekova-na-osnovnu-i-dopunsku-listu/
(Accessed on June 02, 2017).
11Act No. 48/1997, on Public Health Insurance, Czech Republic.
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TABLE 2 | Pricing policy in analyzed CEE countries.
Aspect required Bulgaria Croatia Czechia Estonia Hungary Latvia Lithuania Poland Romania Slovakia
Is external (international) reference pricing
obligatory?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Number of reference countries considered
while external reference pricing
17 5 23 3 31 7 8 31 27 28
Is internal reference pricing obligatory? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
pharmaceutical available in the Czech Republic or in the
reference basket countries. For highly innovative drugs, it is
possible to set the ex-factory price as the average manufacturer’s
price revealed in at least 2 reference basket states.
Currently, in Czech Republic the price and reimbursement of
the first generic product has to be at least 40% lower than the
price and reimbursement of the reference drug. In the case of
other generic product the only the price is decreased. Similarly,
in the case of biological products, the price and reimbursement
have to be at least 30% lower.
In Estonia, the price of especially expensive drugs is usually
negotiated between the Ministry of Social Affairs, Health
Insurance Fund, and the pharmaceutical company. The main
measures are external price referencing and price comparisons
with other similar medicines. Thus, both external and internal
pricing is applied but also the following criteria are used:
• a generic needs to be 30% cheaper than the originator in the
same group,
• a biosimilar needs to be 15% cheaper than the originator in the
same group,
• a parallel imported medicine needs to be 10% cheaper than the
originator in the same group,
• in a reference group, the first 3 medicines with the same active
substance and the same route of administration should be
10% cheaper from each other and the next medicines to be
included into this group should not be more expensive than
the cheapest medicine in this group (Regulation of Ministry of
Social Affairs, 2004).
Manufacturers in Hungary are free to determine the
manufacturing price of their pharmaceutical products; however,
they may be forced to decrease the proposed price during
the procedure for inclusion of a product into reimbursement.
External and internal price referencing is applied for reimbursed
innovative and off-patent medicines, respectively. In case of
external price referencing, all EUmember states are the reference
countries12, the lowest price within the basket of countries is
defined as the reference price. In internal price referencing, the
lowest price drug is the reference product, with a predefined
percent of reimbursement. Drugs with a slightly higher price
receive the same amount of reimbursement but with a higher
copayment. Drugs with significantly higher price are delisted
from reimbursement. From 2011, a blind bidding procedure is
12Decree 32/2004 (26 April) of the Ministry of Health, Social and Family Affairs.
http://net.jogtar.hu/jr/gen/hjegy_doc.cgi?docid=A0400032.ESC (Accessed on June
02, 2017).
used to set the generic reference price. Every 6 months, generic
manufacturers may submit their price reduction proposals, but
without knowing the proposals submitted by their competitors.
After the closure of the bidding process, the drug with the lowest
price becomes the reference product. Products with less than
15% price differential have equal amount of reimbursement with
the reference product, while products with more than 15% price
difference compared to the reference product can have only 85%
of the reimbursement given to the reference product.
In Latvia, the price should not exceed the prices used in
Estonia and Lithuania, and the third lowest price in Czech
Republic, Romania, Slovakia, Hungary, and Denmark. All drugs
with the same indication are reimbursed at the same rate. In
the case of pharmaceuticals with calculated reference price,
the reimbursement rate is applied to the reference price.
The products are grouped into clusters within the INN or
within the pharmacotherapeutic group if there are no clinically
relevant differences in the efficacy and safety profile for the
same indication and drugs are intended for the same patients’
group; the products are clustered according to the dosage and
pharmaceutical form. Then the reference product for each cluster
is identified (the cheapest pharmaceutical), and on the basis of the
price of the reference product the reimbursement price for each
pharmaceutical in the cluster is calculated.
In Lithuania, the declared price of the first generic in a group
should be 50% lower than the price of the original product, price
of the second generic must be at least – 15% lower than the first
generic, and the third generic–15% lower than the second one.
Declared price of biosimilars should be at least 30% lower than
that of original product13.
In Poland, external reference pricing and internal reference
pricing (reimbursement limit is set for each cluster) are valid, but
also value-based pricing (somehow linked to threshold prices in
the economic analysis) is under consideration and influences the
price of a drug. The maximum price of generic product cannot
exceed 75% of the only drug with this active substance. After
evaluation performed by the Polish HTA Agency (pol. Agencja
Oceny Technologii Medycznych i Taryfikacji), negotiations with
the Economic Committee in the Ministry of Health are crucial.
In Romania, Emergency Ordinance no. 59/28.09.201614
established the methodology regarding the calculation,
13Resolution of the Government of the Republic of Lithuania, https://www.e-tar.
lt/portal/lt/legalAct/TAR.9E67C6BA5E0E (Accessed on June 02, 2017).
14Emergency Government Ordinance no. 59/28.09.2016 regarding amendment of
Law no. 95/2006 on healthcare reform, Romanian Official Gazette 768/ September
30, 2016.
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TABLE 3 | Reference countries considered while external reference pricing.
Country Bulgaria Croatia Czechia Estonia Hungary Latvia Lithuania Poland Romania Slovakia Number of referencing
countries∧
Austria 4
Belgium 6
Bulgaria 5
Cyprus 4
Czechia 8
Croatia 5
Denmark 7
Estonia 7
Finland 6
France 7
Germany 4
Great Britain 5
Greece 6
Hungary 7
Iceland 4
Ireland 4
Italy 7
Latvia 8
Liechtenstein 4
Lithuania 8
Luxembourg 4
Malta 4
Netherlands 5
Norway 3
Poland 6
Portugal 6
Romania 6
Slovakia 9
Slovenia 6
Spain 7
Sweden 5
Switzerland 3
∧ number of countries which refer to the particular one. Reference countries are marked in green.
procedure for endorsement and approval of the maximum
prices of medicinal products licensed on the Romanian
pharmaceutical market, except medicines obtained without a
prescription (over-the-counter)15. The manufacturer’s price
should be lower than or equal to the price of the same product
from the list of reference countries. If the drug does not have
an established price in any of 12 countries, it must be lower
than or equal to the price of the same drug in the country of
origin. The reference price of the generic is 65% compared to
the producer price of innovative drug. Generic reference price
remains unchanged, despite the change in price of innovative
drug. The biosimilar reference price represents 80% of the
15Government Decision no. 800/26.10.2016 October 31, 2016 approving the
methodology regarding the calculation method and procedure for endorsement
and approval of the maximum prices of drugs in Romania, Romanian Official
Gazette 869/October 31, 2016.
producer price of the reference biologic drug14,15. Updating
the reference prices for generics and biosimilars is done
annually in October by applying the latest average exchange
rate (set for third quarter) of RON to EUR by the Romanian
National Bank.
Slovakia has implemented a reference pricing system for
medicines, and a maximum price is set for a standard daily
dose in each specific reference group of medicines based on
that system. All medicines included in such reference group
[medicines with the same 5-digit Anatomical Therapeutic
Chemical (ATC) classification system code] contain the same
active substance per dose and are administered in the same
form. Besides, internal reference pricing is applied to some
therapeutic groups which form internal reference groups of drugs
that have the same molecular structure (medicines with the same
4-digit ATC code). Likewise, a maximum price for a standard
daily dose of drugs belonging to the same internal reference
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group is defined. As a result, prices of pharmaceuticals with
different active substances are linked to the cheapest alternative
within an internal reference group. Changes in price for a
particular medicine may thus influence the reimbursement of
other medicines in the same internal or external reference group.
The maximum price of the first generic product cannot exceed
65% of the original drug with this active substance, and the
maximum price of the first biosimilar product cannot exceed 80%
of the biological drug with this active substance16.
A Review of Reimbursement Policies in
Considered CEE Countries
In considered countries, diversified legislation and requirements
concerned reimbursement policy are in use. Details on those
issues were presented in Tables 4–6.
In Bulgaria, a Positive Drug List (PDL) is essentially used; it
consists of 4 appendixes:
• Medicines paid by the National Health Insurance Fund for
outpatients,
• Medicines paid from the hospital budget for inpatients,
• Medicines paid by the budget of the Ministry of Health—
medicines for the diseases which are out of the scope of Health
Insurance, e.g., tuberculosis, HIV/AIDS, as well as vaccines for
obligatory immunization,
• prices of all medicines in PDL including: manufacturer
price, wholesale and retail margins expressed as value and
percentage, value added tax.
Copayment is valid only in case of drugs listed in appendix 1, for
outpatient care. The reimbursement levels are as follows:
• 100% for the medicines indicated in the therapy of chronic
diseases, leading to severe disruptions in the quality of life or
disablement and requiring prolonged treatment,
• 75% for the medicines for diseases with a chronic course and
widespread prevalence,
• 25 or 50% for the medicinal products for the diseases other
than those mentioned above.
The reimbursement level depends on the type of the disease,
the type of a treatment (essential, symptomatic, palliative,
etc.), clinical significance, and budget resources allocated for
procurement of the medicine. The copayment vary depending
on the disease (socially important diseases and rare diseases
have higher reimbursement level) and the results of product’s
assessment (efficacy/therapeutic effectiveness, safety, and
pharmacoeconomic criteria).
In Croatia, there are two positive reimbursement lists: the
essential (basic) list of medicines, and the supplementary list
of medicines9,10. The CHIF covers costs of a drug from a
supplementary list at the price of an equivalent drug specified
under the essential list. The rest of the amount is covered by
an individual copayment. Copayments are required only for
16Act No. 363/2011 Coll. on the scope and conditions of payments for medicines,
medical devices and dietetic foods from public health insurance and amending
certain acts, as amended. http://www.zakonypreludi.sk/zz/2011-363 (Accessed on
June 02, 2017). TA
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TABLE 5 | Reimbursement levels in considered CEE countries.
Bulgaria Croatia Czechia Estonia Hungary Latvia Lithuania Poland Romania Slovakia
Level of
reimbursement
100,
75,
50,
25%
100 or
80%
There are no levels
or categories of
co-payments
100,
90,
75,
50%
Normative
reimbursement: 25,
55, 80%
Indication-linked
reimbursement: 50, 70,
90, 100%
100,
75,
50%
100,
90,
80,
50% - list A
100,
50% - list B
100% - list C
100,
70,
50%
Flat price
co-payment
90% - list A
50, 90% - list B
100% - list C
20% - list D
100%
or partial (between
0 and 100%)
pharmaceuticals which are on the supplementary list of drugs.
The essential (basic) list of medicines contains medications
clinically and economically most appropriate for the treatment
of diseases. The official price of reimbursed drug is established
in the public bidding procedure according to special regulations.
The supplementary list of medicines contains drugs with a higher
level of prices compared to the prices of drugs from the essential
list. The cost of drugs from the supplementary list is covered by
CHIF at the price specified under a special law of an equivalent
drug from the essential list of medicines and additional cost has
to be covered by patient as a copayment.
Copayment does not vary depending on product, patient, or
characteristics of the disease, and it is the same for all drugs. The
drugs are included in the list of drugs through the expert council
of the CHIF and the process is transparent.
In Czech Republic, there is a limit for yearly copayment of
5000 CZK (approx. 190 EUR) for children up to 18 years of age
and 2500 CZK (approx. 95 EUR) for seniors over 65 years of age
(i.e., cap for supplementary payment). According to legislation
(Act. No. 48/1997), the State Institute for Drug Control (Czech,
Státní ústav pro kontrolu léčiv, SUKL) once in the course of 5
years is obligated to make a complex review of reimbursement
level and prices of all pharmaceuticals which belong to specific
groups or therapeutic clusters of pharmaceuticals (so-called
reference groups). These reference groups are formed by
pharmaceutical products which have similar efficacy, safety, and
position in clinical practice. Through these complex reviews, the
level and conditions for reimbursement of all pharmaceutical
products are re-evaluated in relation to evidence based medicine
and valid clinical guidelines. SUKL also carries out simple short-
term reviews initiated when the first generics enter the market
or if a reduction of the price of a particular drug can create
substantial savings in a whole reference group. SUKL is also
obligated to assure that at least 1 product in each therapeutic
group which are defined in Act. No. 48/1997 is fully reimbursed.
Public payers can also initiate the simple short-term reviews of
the reference groups if they expect substantial savings17,18.
In Estonia, patients’ copayments for reimbursed drugs are as
follows:
• 1.27 EUR for medicines reimbursed at 100% level,
17http://www.sukl.eu/sukl/list-of-reimbursed-medicinal-products-1., (Accessed
on June 02, 2017).
18http://www.sukl.cz/sukl/seznam-leciv-nehrazenych-ze-zdravotniho-pojisteni.,
(Accessed on June 02, 2017).
• 1.27 EUR and additionally 10% of the price exceeding the
agreement price for medicines reimbursed at 90% level,
• 1.27 EUR and additionally 25% of the price exceeding
the agreement price for medicines reimbursed at 75%
level,
• 3.19 EUR and additionally 50% of the price exceeding the
agreement price for medicines reimbursed at 50% level19.
The reimbursement rate depends on the severity of condition
or specific disease. This means that there is a list of diseases
established by the Ministry of Social Affairs for which the
medicines need to be reimbursed with specific percentage level20.
This arrangement is similar to that in Latvia.
In Hungary, the reimbursement levels are established
according to the specifications of the therapies; the more severe
and chronic the disease, the higher the reimbursement level is.
In the case of outpatient setting:
• normative reimbursement applies to all physicians with
general prescription rights and may be used for all indications
listed in the Summary of Product Characteristics (SPC); this
technique is associated with a reimbursement level of 25, 55,
and 80%, resulting in a level of patient’s copayment of 75, 45,
and 20%, respectively;
• indication-linked reimbursement restricts reimbursement to
only certain professionals who can prescribe the drug; the
reimbursement is granted only in a subgroup of authorized
indications and is granted if the conditions defined by the
payer are met; the level of reimbursement is 50, 70, 90, and
100%, resulting in a level of patient’s copayment of 50, 30, 10,
or 0%; for each unit, there is a fixed prescription fee of 300
HUF (1 EUR is approximately 315 HUF [2016]) for drugs with
0% copayment.
For off-patent products, the lowest price of a drug is the reference
price which has a predefined percentage of reimbursement.
Medicines with slightly higher price receive the same amount
of reimbursement, but with higher copayment. Drugs with
significantly higher price are delisted from reimbursement. In the
case of inpatient setting, there is no copayment.
19Regulation of Ministry of Social Affairs in Estonia: Co-payment rates. https://
www.riigiteataja.ee/akt/128092012015 (Accessed on June 02, 2017)∼Regulation of
Ministry of Social Affairs in Estonia: Co-payment rates. https://www.riigiteataja.
ee/akt/128092012015 (Accessed on June 02, 2017).
20Health Insurance Act; Estonia https://www.riigiteataja.ee/en/eli/ee/Riigikogu/
act/529122016002/consolide (Accessed on June 02, 2017).
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In Latvia, medicinal products are reimbursed depending on
the diagnosis; reimbursement categories are set according to the
severity of the disease and are as follows:
• 100% reimbursement – for chronic, life threatening diseases
or diseases causing irreversible disability, where the use
of pharmaceuticals ensures and maintains the patient’s life
functions,
• 75% reimbursement – for chronic diseases, for which the
maintenance of the patient’s life functions are aggravated
without the use of pharmaceuticals,
• 50% reimbursement – for vaccines and for diseases where
pharmaceuticals maintain or improve patient’s health.
Patients have to pay the copayment in the case of the 75 and 50%
reimbursement levels21.
In Lithuania, the following reimbursement levels are
applied:
• 100, 90, 80, 50% of reimbursed price according to list A (the
list of diseases and medicines); the level of reimbursement
depends on the severity, disablement and chronic course of
disease,
• 100, 50% of reimbursed price according to list B (the list of
medicines for certain social groups); 100% reimbursement for
children, 50% for pensioners,
• 100% of reimbursed price for medicinal aid for outpatient care
according to list C.
• The following reimbursement levels are employed in Poland:
• 50% and costs above the reimbursement limit,
• 30% and costs above the reimbursement limit,
• flat price over reimbursement limit,
• free of charge (e.g., drug programs for oncology patients,
chemotherapy, patients older than 75 years, war-disabled).
The reimbursement levels depend on the type and duration
of the disease and treatment costs (Kawalec and Malinowski,
2016; Jahnz-Rózyk et al., 2017). Drugs used in inpatient care
are fully covered from public funds via drug programs or
catalog of chemotherapy. They can also be reimbursed indirectly
within hospitalizations (Diagnosis-related Groups) or medical
procedures carried out in hospitals.
In Romania, there are copayments for pharmaceuticals. There
are 4 reimbursement lists: list A (reimbursement rate 90%), list B
(50%), list C (100%) divided into sub-lists C1, C2, and C3, and
list D (20%). Even if a drug is on list C, copayments could be
required, and even if a drug is on list A (90%), copayments do
not have to be required. If a drug from the list B is prescribed for
a pensioner with small pension, it becomes 90% compensated.
Copayments vary based on patient characteristic (age, income)
or condition (chronic or acute/subacute).
In Slovakia, there are the following reimbursement levels:
100% or partial reimbursement (between 0 and 100%). The
decision on reimbursement levels for medicines eligible for
partial reimbursement is based on the following criteria:
21Positive list, Latvia. http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/
kompensejamo-zalu-saraksts (Accessed on June 02, 2017).
therapeutic benefit of the medicine, its final retail price (cost-
effectiveness), and the prices of other reimbursed medicines
within the same reference group16.
There is always at least 1 medicine available in a determined
therapeutic class with no copayment. Copayments do not vary
based on indication, effectiveness, or innovation, but they can
vary based on age, income, characteristics, or condition of
disease. There are drugs in Slovakia which are fully covered
for vulnerable people (e.g., disabled people, retired people,
children)16.
Specific Measures for the Assessment of
Medicines, Particularly Costly
Pharmaceuticals
In Bulgaria, there are obligatory discounts for all costly
medicines, but they are confidential between the MAH and the
public fund. For medicines paid by hospitals, public tenders are
employed. RSAs, usually in a form of price volume agreements,
are also used and they constitute one of the conditions for
inclusion in the PDL. In some cases, a cap for patients is used
as part of the RSA.
In Croatia, there are specific measures for assessment of drugs
such as value-based pricing, rebates, and public tendering. RSAs
are available especially for the biological or biosimilar drugs.
In Czech Republic highly innovative drugs can get temporary
reimbursement for up to 3 years even without relevant cost-
effectiveness and BIA, which means an accelerated entry to the
market. However, after 3 years of temporary reimbursement, they
have to meet cost-effectiveness and budget impact criteria to
get permanent reimbursement. Health care funds can also cover
the cost of a product which is not reimbursed (usually not in a
particular off-label indication), based on individual application
filed for a specific patient by a physician.
RSAs or cap budget limits agreed between MAH and payers
can be a necessity for coping with the required HTA parameters,
especially in the case of new, costly molecules. However,
no agreements (budget cap, RSA) are legally required as a
condition for reimbursement. Legally, there is no formal cap for
reimbursement for an individual patient.
In Estonia RSAs are rare, because they constitute a high
administrative burden to the Health Insurance Fund. The
price of costly medicines is usually negotiated between the
Ministry of Social Affairs, Health Insurance Fund and the
Marketing Authorization Holder. Additional reimbursement
from Health Insurance Fund is possible when patient’s payments
per prescription medicines exceeds 300 EUR per year.
In Hungary, managed entry agreements are mandatory
conditions for reimbursing any new drugs, and obligatory
contribution of manufacturers for reimbursed pharmaceuticals
are as follows (these conditions are determined in the Act XCVIII
of 2006):
• 20% of the reimbursement amount calculated on ex-factory
price level as payback for all reimbursed drugs,
• 10% tax for innovative drugs with a history of at least 6 years of
reimbursement and without reimbursed generic alternatives.
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Additionally, central tenders are used as itemized reimbursed
technique for high-pricedmedicines22. There are also prescribing
quotas for physicians to prescribe a predefined percentage of
preferred reference product within their prescription.
In Latvia, managed entry agreements are allowed by
legislation. RSAs are used in a form of simple discounts,
price-volume agreements and payback. In some cases pay-per-
performance are used.
In Lithuania, RSAs, pay-for-performance agreements and
fixed volume agreements are used to optimize expenditure for
costly medicines. Public tendering is obligatory for purchases of
medicines for hospitals.
In Poland, fixed price is used in the case of ambulatory drugs
(no tendering) but in the case of reimbursed ambulatory drugs
the maximal price is used (Kawalec andMalinowski, 2016; Jahnz-
Rózyk et al., 2017). Public tendering is obligatory for purchases of
medicines for public hospitals. On retail market, any rebates are
prohibited (fixed pricing) but in the case of hospitals rebates or
discounts are allowed.
In Romania, cost-volume contracts and cost-volume-
outcome contracts are applied. Pure RSAs are not available in
reimbursement decision making, but a clawback tax is applied,
that is, manufactures of drugs must return some of the profits
made from sales of free/compensated drugs.
In Slovakia, there are special assessment criteria for highly
innovative medicines which have no treatment alternatives
(including orphan drugs)—the threshold value used in cost-
effectiveness analysis is not applicable for this type of drugs.
The reimbursement decision is made after negotiations between
MAH and health insurance companies. Usually, price discounts
or price limits are offered for public reimbursement and RSAs are
rarely used in Slovakia.
A Review of Health Technology
Assessment in CEE Region Countries
Czech Republic, Estonia, Latvia, Lithuania and Slovakia require
the same set of HTA documentation, including systematic
review, pharmacoeconomic analysis, and BIA. In Hungary,
additional data is required, such as drug prices review in
reference countries, indication and targeted reimbursement level,
and pharmacoeconomic studies from other countries22 (see
Tables 7, 8 for details).
In Bulgaria, a full HTA is performed for medicinal products
belonging to a new INN group, which is not included in
the Positive Drug List; HTA dossier could also be submitted
for a new pharmaceutical form, new dosage form, and for
biosimilars. Minister of Health issued HTA guidelines in a form
of a Regulation, and all submitted HTA dossier must fulfill
them. The HTA Commission, responsible for conducting the
assessment of health technologies, is a group of representatives
of: National Council, Ministry of Health, Bulgarian Drug Agency,
National Health Insurance Fund, and National Centre for Public
Health. The National Council for Pricing and Reimbursement of
22Decree No. 9/1993. (IV. 2.) NM of the Minister of Welfare on the Social
Insurance Financing of Specialist Services [cited 4 April 2017]. https://net.jogtar.
hu/jr/gen/hjegy_doc.cgi?docid=99300009.nm. (Accessed on June 02, 2017). TA
B
L
E
7
|
H
e
a
lth
Te
c
h
n
o
lo
g
y
A
ss
e
ss
m
e
n
t
in
c
o
n
si
d
e
re
d
C
E
E
c
o
u
n
tr
ie
s.
A
s
p
e
c
t
re
q
u
ir
e
d
B
u
lg
a
ri
a
C
ro
a
ti
a
C
z
e
c
h
ia
E
s
to
n
ia
H
u
n
g
a
ry
L
a
tv
ia
L
it
h
u
a
n
ia
P
o
la
n
d
R
o
m
a
n
ia
S
lo
v
a
k
ia
Is
H
TA
d
o
ss
ie
r
o
b
lig
a
to
ry
in
p
ric
in
g
a
n
d
re
im
b
u
rs
e
m
e
n
t
su
b
m
is
si
o
n
?
Y
e
s
N
o
b
u
t
a
lte
rn
a
tiv
e
a
ss
e
ss
m
e
n
t
h
a
s
to
b
e
su
b
m
itt
e
d
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
In
c
a
se
if
H
TA
is
n
o
t
o
b
lig
a
to
ry
it
c
o
u
ld
b
e
su
b
m
itt
e
d
w
ith
a
re
im
b
u
rs
e
m
e
n
t
a
p
p
lic
a
tio
n
a
s
a
a
d
d
iti
o
n
a
lf
a
c
u
lta
tiv
e
d
o
ss
ie
r?
It
’s
o
b
lig
a
to
ry
Y
e
s
It
’s
o
b
lig
a
to
ry
It
’s
o
b
lig
a
to
ry
It
’s
o
b
lig
a
to
ry
It
’s
o
b
lig
a
to
ry
It
’s
o
b
lig
a
to
ry
It
’s
o
b
lig
a
to
ry
It
’s
o
b
lig
a
to
ry
It
’s
o
b
lig
a
to
ry
A
re
H
TA
g
u
id
e
lin
e
s
o
b
lig
a
to
ry
fo
r
su
b
m
itt
e
d
H
TA
d
o
ss
ie
r
a
tt
a
c
h
e
d
to
th
e
re
im
b
u
rs
e
m
e
n
t
a
p
p
lic
a
tio
n
?
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
Y
e
s
W
h
a
t
in
st
itu
tio
n
s
a
re
re
sp
o
n
si
b
le
fo
r
d
e
te
rm
in
in
g
“b
e
n
e
fit
”
a
n
d
“v
a
lu
e
”
o
f
p
h
a
rm
a
c
e
u
tic
a
ls
?
H
TA
C
o
m
m
is
si
o
n
N
a
tio
n
a
lC
o
u
n
c
il
M
in
is
tr
y
o
f
H
e
a
lth
T
h
e
C
H
IF
a
n
d
th
e
ir
E
xp
e
rt
c
o
u
n
c
il
o
f
th
e
C
H
IF
S
ta
te
In
st
itu
te
fo
r
D
ru
g
C
o
n
tr
o
l(
S
U
K
L
)
M
in
is
tr
y
o
f
S
o
c
ia
l
A
ffa
irs
H
e
a
lth
In
su
ra
n
c
e
F
u
n
d
T
h
e
N
a
tio
n
a
lI
n
st
itu
te
o
f
H
e
a
lth
In
su
ra
n
c
e
F
u
n
d
M
a
n
a
g
e
m
e
n
t
(s
in
c
e
2
0
1
6
)
T
h
e
H
TA
O
ffi
c
e
a
t
th
e
N
a
tio
n
a
lI
n
st
itu
te
o
f
P
h
a
rm
a
c
y
a
n
d
N
u
tr
iti
o
n
T
h
e
M
e
d
ic
a
lP
ro
fe
ss
io
n
a
lC
o
lle
g
e
s
T
h
e
Te
c
h
n
o
lo
g
y
A
ss
e
ss
m
e
n
t
C
o
m
m
itt
e
e
T
h
e
N
a
tio
n
a
lH
e
a
lth
S
e
rv
ic
e
o
f
L
a
tv
ia
M
in
is
tr
y
o
f
H
e
a
lth
T
h
e
S
ta
te
M
e
d
ic
in
e
s
C
o
n
tr
o
l
A
g
e
n
c
y
N
a
tio
n
a
lH
e
a
lth
In
su
ra
n
c
e
F
u
n
d
u
n
d
e
r
th
e
M
in
is
tr
y
o
f
H
e
a
lth
P
o
lis
h
H
TA
A
g
e
n
c
y
(A
g
e
n
c
y
fo
r
H
e
a
lth
Te
c
h
n
o
lo
g
y
A
ss
e
ss
m
e
n
t
a
n
d
Ta
rif
f
S
ys
te
m
s;
A
O
T
M
iT
)
N
a
tio
n
a
lA
g
e
n
c
y
fo
r
M
e
d
ic
in
e
s
a
n
d
M
e
d
ic
a
l
D
e
vi
c
e
s
in
R
o
m
a
n
ia
S
lo
va
k
M
in
is
tr
y
o
f
H
e
a
lth
T
h
e
R
e
im
b
u
rs
e
m
e
n
t
C
o
m
m
itt
e
e
Frontiers in Pharmacology | www.frontiersin.org 11 December 2017 | Volume 8 | Article 892
Kawalec et al. Pharmaceutical Regulation in CEE Countries
T
A
B
L
E
8
|
O
b
lig
a
to
ry
p
a
rt
s
o
f
H
TA
d
o
ss
ie
r
in
c
o
n
si
d
e
re
d
C
E
E
c
o
u
n
tr
ie
s.
T
y
p
e
o
f
a
n
a
ly
s
is
B
u
lg
a
ri
a
C
ro
a
ti
a
C
z
e
c
h
ia
E
s
to
n
ia
H
u
n
g
a
ry
L
a
tv
ia
L
it
h
u
a
n
ia
P
o
la
n
d
R
o
m
a
n
ia
S
lo
v
a
k
ia
C
lin
ic
a
la
n
a
ly
si
s
+
−
+
+
+
+
+
+
−
+
P
h
a
rm
a
c
o
e
c
o
n
o
m
ic
a
n
a
ly
si
s
(c
o
st
e
ff
e
c
tiv
e
n
e
ss
c
o
st
u
til
ity
o
r
c
o
st
m
in
im
a
liz
a
tio
n
)
+
−
+
+
+
+
+
+
−
+
B
u
d
g
e
t
im
p
a
c
t
a
n
a
ly
si
s
+
+
+
+
+
+
+
+
+
A
si
m
p
le
b
u
d
g
e
t
im
p
a
c
t
m
o
d
e
l(
o
n
ly
d
ire
c
t
c
o
st
s)
+
O
th
e
r
a
n
a
ly
se
s
u
se
d
in
re
im
b
u
rs
e
m
e
n
t
a
p
p
lic
a
tio
n
p
ro
c
e
ss
E
th
ic
a
l
c
o
n
si
d
e
ra
tio
n
s
−
−
−
D
ru
g
p
ric
e
in
o
th
e
r
c
o
u
n
tr
ie
s
a
ss
e
ss
m
e
n
t,
re
q
u
e
st
e
d
in
d
ic
a
tio
n
a
n
d
ta
rg
e
te
d
re
im
b
u
rs
e
m
e
n
t
te
c
h
n
iq
u
e
/l
e
ve
l,
p
h
a
rm
a
c
o
e
c
o
n
o
m
ic
st
u
d
ie
s
fr
o
m
o
th
e
r
c
o
u
n
tr
ie
s
−
−
D
e
c
is
io
n
p
ro
b
le
m
a
n
a
ly
si
s,
ra
tio
n
a
liz
a
tio
n
a
n
a
ly
si
s
H
TA
fr
o
m
F
ra
n
c
e
,
G
e
rm
a
n
y
a
n
d
U
K
,
n
u
m
b
e
r
o
f
E
U
c
o
u
n
tr
ie
s
w
ith
a
p
o
si
tiv
e
re
im
b
u
rs
e
m
e
n
t
st
a
tu
s,
re
a
l-
w
o
rld
d
a
ta
(R
W
D
)
st
u
d
y
−
Medicinal Products is responsible for pricing and for inclusion of
medicinal product in PDL. It is a state commission, andmembers
are elected by the Council of Ministers.
According to the Act No. 48/1997, HTA process in Czech
Republic is an obligatory part of reimbursement decision-
making process. HTA guidelines, according to which SUKL
makes assessment of HTA dossiers, are publicly available and
compliance with these guidelines is highly recommended23.
In Croatia, the criteria for inclusion of medicines in the
reimbursement list are as follows: the importance of the drug
from the standpoint of public health, the therapeutic importance
of the drug, relative therapeutic value of the drug, and the
assessment of the ethical aspects9,10. HTA dossier could be
submitted with a reimbursement application as an additional,
facultative dossier, but the Budget Impact Analysis is obligatory
for submission, while systematic review/clinical analysis and
pharmacoeconomic analysis are not obligatory (except in specific
cases). It is required that BIA contains 2 scenarios of the
analytical model, where one takes into account only the direct
costs of the drug and the other contains all the additional direct
costs arising from placing the drug on the reimbursement list.
MAHs submit the proposal for inclusion of a new drug on the
reimbursement list or the expansion of indications of the already
included drug. Guidelines for the BIA issued by the CHIF include
basic methodology requirements for BIAs and are in accordance
with the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) guidelines (Weinstein et al., 2003;
Mauskopf et al., 2007).
The Agency for Quality and Accreditation in Health Care
is responsible for the HTA process in Croatia. The activity of
the agency contains national collaboration, education, and the
HTA promotion, international collaboration (EU Projects), the
establishment of the Croatian HTA Guideline, and the creation
of the HTA reports and scientific publications (Voncina and
Strizrep, 2010; Vogler et al., 2011). The assessment process starts
with a pre-assessment of the existing evidence on each selected
topic, prepared by the HTA Department. It is intended that the
HTA Agency will take part in future pricing and reimbursement
decisions because currently its activity is still on the level of
recommendation.
In Lithuania, the national HTA agency has not been
established till now. Assessment of dossier for reimbursement
is performed by three institutions: State Medicines Control
Agency—therapeutic value, Department of Pharmacy of
Ministry of Health—pharmacoeconomic value, and National
Health Insurance Fund (NHIF)—budget impact assessment.
Therapeutic value of the product assessment is based on the
innovativeness (2–5 points) and therapeutic benefit for patients
(3–10 points). Pharmacoeconomic value score is a composite of
relative pharmacieconomic value and declared price scores, and
may range from 1.5 to 7.5.
Recommendations on reimbursement are issued by the
Committee of reimbursement, and are following:
23http://www.sukl.cz/leciva/metodiky-stanoveni-cen-a-uhrad., (Accessed on June
02, 2017).
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• the medicine is recommended to be included to positive list A
if therapeutic value is ≥ 9, pharmacoeconomic value ≥ 4, and
there is negative (neutral) impact on NHIF budget;
• the medicine is recommended to be included to the waiting
list, if therapeutic value is≥ 11, pharmacoeconomic value≥ 4,
and there is positive impact on NHIF budget;
• the medicine is not recommended for reimbursement, if
therapeutic value is < 9, pharmacoeconomic value < 4.
Waiting list is revised every half a year, and medicines
are included to the Positive list if payers budget is able
to afford it. Recommendation of reimbursement committee
goes to Obligatory Health Insurance Council, which issues
recommendation to the Minister of Health.
In Poland, HTA is obligatory in the application process for
reimbursement. The full HTA report has 3 basic components:
clinical analysis, economic analysis, and BIA. The clinical
analysis evaluates the clinical efficacy and safety profile. The
economic analysis informs whether the use of a new, reimbursed
drug in place of standard therapy is cost-effective. In other
words, the analysis has to determine whether the marginal
cost per quality-adjusted life-years gained is below the cost-
effectiveness threshold of 130,000 PLN (3 × Gross Domestic
Product per capita). Finally, the BIA assesses the financial
burden of a reimbursement decision for the National Health
Fund. Rationalization analysis is performed only if the BIA
revealed additional costs for public payer resulted from the
reimbursement of assessed technology; this analysis has to
provide proposals of rationalization solutions, implementation of
which should generate savings in an amount equaled at least the
value of additional costs revealed in the BIA24.
Reimbursement application should be submitted to the
Ministry of Health with HTA dossier. Based on the submitted
dossier, the President of the AHTAPol issues 3 types of
recommendations. The first type is positive recommendation,
which supports coverage from the public budget. The second
type is conditional—the reimbursement is possible but additional
conditions have to be met (e.g., price reduction, RSA). A
negative recommendation advocates lack of coverage from
public resources. After the AHTAPol issues its recommendation,
negotiations with the Economic Committee of the Ministry
of Health (official price terms of reimbursement) are crucial
for reaching a final decision on reimbursement (Kawalec and
Malinowski, 2016)24.
In Romania, HTA dossier is obligatory in reimbursement
submission for a new molecules, compensated molecules for
indication expansion, and generics or biosimilars that do not
have compensated molecules in the list. The scorecard HTA
model was established in 2014 and it was based on the analysis
of 6 criteria: HTA decisions from France, Germany, and UK,
the number of EU countries (27 countries) in which the drug
is reimbursed, and a BIA focusing on direct costs. A full HTA
dossier can be submitted with a reimbursement application as
additional facultative dossier25.
24http://www.aotm.gov.pl/www/, January 2016 (Accessed on June 02, 2017)
25Ministry of Health Order No. 487/2017 regarding the approval of criteria for
evaluation of medical technologies, the documents to be submitted by solicitants,
Romanian HTA guidelines in its current version make a
comprehensive evaluation of the technology impossible because
they take into account only cost-saving aspect and ignore the
efficacy and safety (Radu et al., 2016). There is a proposed
transition to a model that also includes studies of cost-
effectiveness and calibration of utility values specific to Romania
(Paveliu, 2013).
In Slovakia, full HTA dossier is not obligatory in pricing
and reimbursement submission for generics and biosimilars.
However, for innovative drugs clinical assessment review,
pharmacoeconomic analysis, and BIA are required. Slovak
Ministry of Health established the Reimbursement (or
Categorization) Committee to act as its advisory body in
reimbursement processes. The Categorization Committee
constitutes of 3 representatives from the Ministry of Health,
5 representatives from health insurance companies and
3 representatives from the Slovak Medical Chamber. The
Categorization Committee is supported by different advisory
working groups, medical board (assessing the effectiveness,
safety, and importance of the medicine) and the Working
Group for Pharmacoeconomics, Clinical Outcomes and
Health Technology Assessment of the Ministry of Health.
Recommendations from the Categorization Committee are the
basis for the Ministry of Health when issues the final decisions
(details in Table 9).
DISCUSSION
Comparative analysis, which included 10 countries, confirmed
that the pricing and reimbursement requirements are quite
similar among the countries of the CEE region. However, some
differences were also identified.
Within this analysis, the expenditures on reimbursement were
also assessed and expressed in relation to the total expenditure
on health. Among the compared countries, the relation of drug
reimbursement costs to total public health care spending was
from 0.12 to 0.21, with a median value between 0.15 and 0.18,
depending on the analyzed year.
In all analyzed countries the reference price system, including
external reference pricing and internal reference pricing, is used.
External reference pricing consists in comparing the prices of
the same product in other countries. Particular countries refer
to different number of countries—from 3 (Estonia, Switzerland)
to as much as 31 (Poland). Slovakia is the most frequently
referenced country, while Cyprus, Iceland, Malta, Luxembourg,
and Norway are countries to which other CEE countries
refer least frequently. Internal reference pricing is meant to
determine pharmaceutical prices based on similar products or
drug equivalents available on pharmaceutical market. It is used
to set reimbursement prices for product groups called clusters.
Pharmaceuticals are clustered according to active substance;
several active substances are clustered together if they are
chemically related and pharmacologically equivalent (Panteli
the process and the methodology used to assess the drugs, the new indications to
be included on the reimbursement list, and the criteria for exclusion of drugs from
the list. Romanian Official Gazette June 28th, 2017.
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TABLE 9 | Determinants for therapeutic and social value of pharmaceuticals in
Slovakia.
Determinants for the therapeutic
value of drugs
Determinants for the social value of
drugs
Effectiveness Severity of the disease
Safety Impact on society if not treated (e.g.,
spread of infection)
Cost-effectiveness Social value (e.g., orphan drugs)
A first or second option or adjunctive
treatment
Risk of abuse
Causal treatment, prophylaxis or a
symptomatic treatment
Impact on total costs
et al., 2016). Value-based pricing has been gaining importance as
an alternative strategy in recent years (Panteli et al., 2016) and
some elements of it are applied in Poland and Hungary.
Considered countries use publicly available price information
which does not present confidential rebates and discounts
negotiated between manufacturers and payers (Panteli et al.,
2016). In all of the countries, reimbursement decision-making
processes in the outpatient sector refer to a PDL (Panteli et al.,
2016); pharmaceuticals are reimbursed once they are included in
the list, except in Bulgaria where new INNs start to be reimbursed
at the beginning of the year after their inclusion. Some countries
apply both a positive and a negative drug list, although the
negative drug list is rare and is present only in 3 countries
(Hungary, Romania and Slovakia). Reimbursement decisions are
regularly revised and updated in almost all of included countries
(except for Hungary and Lithuania), most commonly using a 2–
12-month window. Ad hoc revisions are additionally carried out
following changes or extensions of an indication, availability of
new evidence or market entry of a therapeutic alternative (Panteli
et al., 2016).Ad hoc revisions are made in Hungary and Lithuania
and they are also possible in Czech Republic and Romania as an
alternative to the periodic revisions.
RSAs become more and more popular in Europe (Panteli
et al., 2016), and they are currently available in all analyzed
CEE countries. The situation looks different in the case of cap
for patients, as they are only used in Estonia and Romania.
Cap for patients are also possible in Slovakia and Bulgaria but
only for the vulnerable groups of patients. Specific discounts are
sometimes used for particularly costly pharmaceuticals. While
such discounts are agreed, rebates are returned to the payer
after the purchase of a pharmaceutical. Discounts and rebates
can be applied universally (legally imposed and pertaining to
all manufacturers and payers in the system) or be negotiated
between individual payers and manufacturers. In the case of
inpatient care, tendering can be employed.
RSAs as informal and confidential agreements influence drug
availability in considered countries as they usually significantly
decrease costs of therapy thus make it possible to reimburse
it for patients. Due to lack of relevant cost data the difference
between official prices and real costs of medicines is a substantial
information gap. Without knowing the figures the possible
effects of RSAs on the national drug policies were very difficult
for evaluation; we could only presume that their influence on
disturbing the transparency of pricing policy could be significant.
Cost sharing usually applies to pharmaceuticals prescribed
in outpatient care and most commonly takes the form of a
percentage share of the retail price of a medicine. The amount
of this share can vary depending on the condition (e.g., chronic
diseases), income or employment status, or age. Copayments
for outpatient care are common and present in all analyzed
countries, which determine the price share to be borne by the
statutory health system as part of the reimbursement decision
for each medicine. The available levels of reimbursement differ
within and between the countries and range from 20 to 100%.
According to our survey only 3 countries in the sample (Czech
Republic, Lithuania, and Slovakia) use additional arrangements
to enable better access to orphan drugs. In Czech Republic,
orphan drugs sometimes meet the criteria for highly innovative
medicines and get temporary reimbursement up to 3 years even
without relevant cost-effectiveness and BIA. In Slovakia special
reimbursement regulations are used in case of orphan drugs
(with prevalence lower than 1: 100,000)—the threshold value
used within the cost-effectiveness analysis is not applicable for
this group of drugs.
Generic substitution is also possible in almost all analyzed
CEE countries, while some make it mandatory (Estonia,
Hungary if available (this is mainly a generic product from
interchangeability list, with the same dose, INN and drug form).
Bulgaria is the only country in which pharmacists cannot make
any changes on the reimbursable prescriptions, because the
coding system use and the details of the MAH, regardless
of whether it is an originator or a generic. In Romania, the
generic substitution is also mandatory, but with some exceptions
as biologic drugs cannot be substituted. To support generic
substitution, prescription of active substance (INN) rather than
trade name has been institutionalized in all countries—in some
countries it is mandatory (Estonia, Lithuania, partially Romania,
and Slovakia), while in others it is optional. Implementation
of relevant regulation also influences the market penetration of
generic products. In terms of volume, the share of generics in
the analyzed CEE countries was on average 60% (median 69%)
and in terms of value it was 33% (median 30%). In terms of
volume, Bulgaria (78%) (Stoimenova et al., 2016), Latvia (77%),
and Romania (75%) take the top 3 places in the sample, while in
terms of value, it was Latvia (59%), Bulgaria (45%), and Poland
(41%). The lowest share of generics was observed in Estonia (36%
in terms of volume and 16% in terms of value).
To increase the access to a drug and bring more stability
in reimbursement and pricing system in Romania, in 2016,
the government issued a decision approving the methodology
regarding the calculation method and the procedure for
endorsement and approval of the maximum prices; the new
methodology will reduce the price of the drugs.
Drugs for compassionate use are reimbursed only in Hungary
and Czech Republic; special early drug access programs tend to
facilitate the availability of new medicines to patients suffering
with life threatening diseases and provide them an access to
drugs not available via standard reimbursement. In Hungary,
the vulnerable patients with very low income are granted a
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monthly individual budget for their essential prescription-only
medicines. In Czech Republic, drugs which are not authorized
may be reimbursed under specific conditions, and additionally
the individual reimbursement is also possible (specific product
for a specific patient after acceptance of individual application by
the payer).
Electronic prescribing is available in some of the countries.
In Bulgaria, Hungary, Poland, Czech Republic, and Slovakia, the
implementation of electronic prescribing is planned.
HTA is carried out in all analyzed CEE countries and HTA
dossier is obligatory in pricing and reimbursement submission.
The only exception is Croatia, where alternative assessment has to
be submitted instead of a HTA dossier. The key analyses included
in HTA dossier are: clinical analysis (obligatory in 8 out of 10
countries), pharmacoeconomic analysis (obligatory in 8 out of 10
countries), and BIA (obligatory in all countries). Other additional
parts of HTA dossier which are obligatory only in some of
the considered countries are: ethical considerations (Bulgaria),
submitting drug price in other countries (Hungary), submitting
published pharmacoeconomic analysis or heath technology
assessments from other countries (Hungary, Romania), decision
problem analysis (Poland), rationalization analysis (Poland).
In all considered countries specific committees responsible
for formulating reimbursement recommendations have been
established. Criteria guiding recommendations as well as final
reimbursement decision-making vary among the countries in
this study. Slovakia has its unique criteria determining the
therapeutic and social value of medicines. It can be assumed
that the therapeutic value is determined in a similar way
in all other countries by considering the following aspects:
effectiveness, safety, cost-effectiveness, whether it is a causal
treatment, prophylaxis, or a symptomatic treatment, whether it
is a first or second option or adjunctive treatment. The following
aspects are taken into account in Slovakia while considering
social value of a medicine: severity of the disease, impact on
society if not treated, social value (e.g., orphan drugs), risk of
abuse, impact on total costs.
The national HTA assessment institutions or authorities are
in some cases also responsible for the final political decision on
reimbursement and/or marketing authorization. In some cases,
for example in Poland, final decisions or their implementation
can differ from the reimbursement recommendations, usually
as a result of budgetary or societal considerations (Kawalec and
Malinowski, 2016).
The current project is quite innovative as we did not identify
any other studies on the similar topic, carried out for CEE
countries. However, some similar reports were found.
In another publication the Hungarian reimbursement system
was presented (Endrei et al., 2014). In this country, there was a
solidarity-based health insurance system with a single payer, and
the National Institute of Health Insurance Fund Management
was the only health care financing agency. The Hungarian
HTA office belonged to the National Institute of Pharmacy and
Nutrition (Országos Gyógyszerészeti és Élelmezés-egézségügyi
Intézet). Hungary adopted the directive on transparency for the
evaluation of new drugs and medical devices applying for health
insurance reimbursement. There were also formal guidelines for
conducting economic evaluation of health care interventions.
Gulacsi et al. (2014) described and discussed the development
and use of HTA in 5 CEE countries: Bulgaria, Czech Republic,
Hungary, Poland, and Romania. The study was based on
document analysis and expert opinion; the similarities and
differences between the particular CEE countries in HTA were
presented. In 4 of the discussed countries, that is, Hungary,
Poland, Romania, and Bulgaria, HTA was embedded in the
law. The Czech Republic had legal embedding of HTA, cost-
effectiveness analysis, and BIA for the purposes of evaluating
therapies. Each of the countries had a HTA body which
played a role in reimbursement decision-making, although
their competences varied. Most bodies produced reimbursement
recommendations based on an evaluation of dossiers provided
by pharmaceutical companies rather than in-depth assessments.
In all countries, except Czech Republic, the final reimbursement
decisions belonged to the ministry of health. Guidelines for HTA
were different in terms of detailed methodology required but
the evaluation of the following issues was generally required:
information on clinical efficacy and safety, systematic reviews,
meta-analysis, epidemiology, results from health economics
analysis, disease burden, and patient-reported outcomes. There
were differences in the criteria for positive recommendations in
the analyzed countries related to safety issues, implementation of
financing thresholds, and the influence of reimbursement status
in other countries.
The time elapsed frommarketing authorization to the starting
date of reimbursement of the original medicines in CEE countries
(Austria, Slovakia, Slovenia, Bulgaria, the Czech Republic, Latvia,
Lithuania, Estonia, Hungary, Poland, and Romania) was analyzed
in the study by Komáromi et al. (2014). The analysis included
216 products and the following indicators were calculated: the
delay between marketing authorization date and reimbursement
date, the number of reimbursed INNs according to a specific
country or MAH, success rate as the ratio of reimbursed
INNs to examined INNs. The average number of days which
elapsed between the authorization and the starting date of
reimbursement differed between the analyzed countries—it
ranged from 403 days in Slovenia to 1,295 days in Poland. The
average value in all included countries was 632 days.
A recent study compared the prices and reimbursement of
cardiovascular medicines in Bulgaria and Romania. The results
showed that the lower margins in Bulgaria may compensate the
higher value-added tax and can lead to lower retail price (Mitkova
et al., 2016).
In the study (Oyebode et al., 2015), all of the specific
requirements for the HTA dossier in individual European
national agencies responsible for reimbursement were collected,
analyzed, and compared. Twenty-nine countries were analyzed,
including some countries from the CEE region. The level of
detail of the required information varied considerably across
countries. Despite differences in quantity and detail, the content
of the evidence requirements was rather similar and the following
points were required: information on target disease, safety and
clinical effectiveness of considered pharmacotherapy.
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CONCLUSIONS
Pricing and reimbursement requirements are quite similar across
the CEE region, although some differences were identified.
External reference pricing as well as internal reference pricing
is common in all analyzed countries. Positive reimbursement
lists are valid in all countries, and negative ones are rarely used.
Reimbursement decisions are regularly revised and updated in
the majority of countries. Copayment is common and available
levels of reimbursement differ within and between the CEE
countries and range from 20 to 100%. Risk-sharing schemes
are often in use, especially in the case of innovative, expensive
drugs. Generic substitution is also possible in the analyzed CEE
countries, while some make it mandatory. HTA is carried out in
the majority of CEE countries and HTA dossier is obligatory in
pricing and reimbursement submission.
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